Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.82 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.82 |
| ▸ | KDR | P35968 | 3/20 | 0.82 |
| ▸ | AURKA | O14965 | 1/20 | 0.82 |
| ▸ | INSR | P06213 | 1/20 | 0.82 |
| ▸ | FBP1 | P09467 | 1/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.82 |
| ▸ | FLT4 | P35916 | 1/20 | 0.82 |
| ▸ | CLK1 | P49759 | 1/20 | 0.82 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.82 |
| ▸ | TEK | Q02763 | 1/20 | 0.82 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968994 | 1.00 | EGFR (0.82) | EGFRERBB2KDRAURKAINSR | |
| Hydrochloric Acid SCHEMBL641764 | 0.99 | EGFR (0.80) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL13006602 | 0.93 | EGFR (0.71) | EGFRERBB2KDRAURKAINSR | |
| Hydrochloric Acid SCHEMBL3722776 | 0.92 | EGFR (0.70) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL14515605 | 0.92 | EGFR (0.69) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL30639946 | 0.91 | EGFR (0.77) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL22630824 | 0.91 | KDR (0.69) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL30505605 | 0.91 | EGFR (1.00) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL2099106 | 0.91 | EGFR (1.00) | EGFRERBB2KDRAURKAINSR | |
| SCHEMBL18660020 | 0.90 | EGFR (0.83) | EGFRERBB2KDRAURKAINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-7803559-B1 | Protein aggregation regulators | THE REGENTS OF THE UNIVERSITY OF CA (US) | 2010-09-28 | — | — | US | claimed |
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-11-21 | — | — | US | disclosed |
| CN-118063399-A | Method for synthesizing N- (3-chloro-4-fluorophenyl) -6-hydroxy-7-methoxy-4-quinazolinamine | 杭州微流汇科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021212536-A1 | METHOD FOR PREPARING 4-(3-CHLORO-4-FLUOROANILINE)-6-ACETOXY-7-METHOXY QUINAZOLINE HYDROCHLORIDE | 江苏天士力帝益药业有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| CN-113444052-A | Synthesis of gefitinib | 江苏君若药业有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-7417055-B2 | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1680426-B1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-7217717-B2 | Phenalene derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1680426-A1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2004111055-A1 | 1.3.4-TRIAZA-PHENALENE AND 1,3,4,6-TETRAAZAPHENALENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040254205-A1 | Phenalene derivatives | LUK KIN-CHUN (US) | 2004-12-16 | — | — | US | disclosed |
| EP-0880507-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030034-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382599-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885ERBB2 6/4885KDR 241/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885KDR 60/4885 |
| US-20040254205-A1 | Phenalene derivatives | EGFR, ERBB2, ERBB4 | EGFR 1/4885ERBB2 2/4885KDR 504/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | EGFR 2/4885ERBB2 6/4885KDR 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.